Literature DB >> 12795588

Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells.

Jean C Lee1, Carolyn V Taylor, Sara P Gaucher, Thomas Toneff, Laurent Taupenot, Sukkid Yasothornsrikul, Sushil K Mahata, Catherine Sei, Robert J Parmer, John M Neveu, William S Lane, Bradford W Gibson, Daniel T O'Connor, Vivian Y H Hook.   

Abstract

Catestatin is an active 21-residue peptide derived from the chromogranin A (CgA) precursor, and catestatin is secreted from neuroendocrine chromaffin cells as an autocrine regulator of nicotine-stimulated catecholamine release. The goal of this study was to characterize the primary sequences of high molecular mass catestatin intermediates and peptides to define the proteolytic cleavage sites within CgA that are utilized in the biosynthesis of catestatin. Catestatin-containing polypeptides, demonstrated by anti-catestatin western blots, of 54-56, 50, 32, and 17 kDa contained NH(2)-terminal peptide sequences that indicated proteolytic cleavages of the CgA precursor at KK downward arrow, KR downward arrow, R downward arrow, and KR downward arrow basic residue sites, respectively. The COOH termini of these catestatin intermediates were defined by the presence of the COOH-terminal tryptic peptide of the CgA precursor, corresponding to residues 421-430, which was identified by MALDI-TOF mass spectrometry. Results also demonstrated the presence of 54-56 and 50 kDa catestatin intermediates that contain the NH(2) terminus of CgA. Secretion of catestatin intermediates from chromaffin cells was accompanied by the cosecretion of catestatin (CgA(344)(-)(364)) and variant peptide forms (CgA(343)(-)(368) and CgA(332)(-)(361)). These determined cleavage sites predicted that production of high molecular mass catestatin intermediates requires cleavage at the COOH-terminal sides of paired basic residues, which is compatible with the cleavage specificities of PC1 and PC2 prohormone convertases. However, it is notable that production of catestatin itself (CgA(344)(-)(364)) utilizes more unusual cleavage sites at the NH(2)-terminal sides of downward arrow R and downward arrow RR basic residue sites, consistent with the cleavage specificities of the chromaffin granule cysteine protease "PTP" that participates in proenkephalin processing. These findings demonstrate that production of catestatin involves cleavage of CgA at paired basic and monobasic residues, necessary steps for catestatin peptide regulation of nicotinic cholinergic-induced catecholamine release.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12795588     DOI: 10.1021/bi0300433

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

Review 1.  Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-01-28

2.  Primary culture of bovine chromaffin cells.

Authors:  Daniel T O'Connor; Sushil K Mahata; Manjula Mahata; Qijiao Jiang; Vivian Y Hook; Laurent Taupenot
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

3.  Proteomics of dense core secretory vesicles reveal distinct protein categories for secretion of neuroeffectors for cell-cell communication.

Authors:  Jill L Wegrzyn; Steven J Bark; Lydiane Funkelstein; Charles Mosier; Angel Yap; Parsa Kazemi-Esfarjani; Albert R La Spada; Christina Sigurdson; Daniel T O'Connor; Vivian Hook
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

4.  Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo.

Authors:  Maple M Fung; Rany M Salem; Parag Mehtani; Brenda Thomas; Christine F Lu; Brandon Perez; Fangwen Rao; Mats Stridsberg; Michael G Ziegler; Sushil K Mahata; Daniel T O'Connor
Journal:  Clin Exp Hypertens       Date:  2010       Impact factor: 1.749

5.  Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin.

Authors:  Nilima Biswas; Sucheta M Vaingankar; Manjula Mahata; Madhusudan Das; Jiaur R Gayen; Laurent Taupenot; Justin W Torpey; Daniel T O'Connor; Sushil K Mahata
Journal:  Endocrinology       Date:  2007-11-08       Impact factor: 4.736

6.  Proteolytic fragments of chromogranins A and B represent major soluble components of chromaffin granules, illustrated by two-dimensional proteomics with NH(2)-terminal Edman peptide sequencing and MALDI-TOF MS.

Authors:  Jean C Lee; Vivian Hook
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

7.  Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure.

Authors:  Daniel T O'Connor; Gu Zhu; Fangwen Rao; Laurent Taupenot; Maple M Fung; Madhusudan Das; Sushil K Mahata; Manjula Mahata; Lei Wang; Kuixing Zhang; Tiffany A Greenwood; Pei-an Betty Shih; Myles G Cockburn; Michael G Ziegler; Mats Stridsberg; Nicholas G Martin; John B Whitfield
Journal:  Circulation       Date:  2008-06-30       Impact factor: 29.690

Review 8.  Antimicrobial peptides: natural effectors of the innate immune system.

Authors:  Katherine Radek; Richard Gallo
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 11.759

9.  Catestatin, an endogenous chromogranin A-derived peptide, inhibits in vitro growth of Plasmodium falciparum.

Authors:  Aziza Akaddar; Cécile Doderer-Lang; Melissa R Marzahn; François Delalande; Marc Mousli; Karen Helle; Alain Van Dorsselaer; Dominique Aunis; Ben M Dunn; Marie-Hélène Metz-Boutigue; Ermanno Candolfi
Journal:  Cell Mol Life Sci       Date:  2009-12-31       Impact factor: 9.261

10.  Cateslytin, a chromogranin A derived peptide is active against Staphylococcus aureus and resistant to degradation by its proteases.

Authors:  Rizwan Aslam; Céline Marban; Christian Corazzol; François Jehl; François Delalande; Alain Van Dorsselaer; Gilles Prévost; Youssef Haïkel; Corinne Taddei; Francis Schneider; Marie-Hélène Metz-Boutigue
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.